Literature DB >> 15174982

The beginning of the end of warfarin?

John W Eikelboom, Graeme J Hankey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15174982     DOI： 10.5694/j.1326-5377.2004.tb06088.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN： 0025-729X            Impact factor:   7.738


× No keyword cloud information.
  4 in total

Review 1.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins.

Authors:  So-Young Kim; Ji-Yeon Kang; Jessica H Hartman; Sun-Ha Park; Drew R Jones; Chul-Ho Yun; Gunnar Boysen; Grover P Miller
Journal:  Drug Metab Lett       Date:  2012-09-01

Review 3.  Ximelagatran: direct thrombin inhibitor.

Authors:  Shir-Jing Ho; Tim A Brighton
Journal:  Vasc Health Risk Manag       Date:  2006

4.  Influence of Shenxiong Glucose Injection on the Activities of Six CYP Isozymes and Metabolism of Warfarin in Rats Assessed Using Probe Cocktail and Pharmacokinetic Approaches.

Authors:  Jia Sun; Yuan Lu; Yueting Li; Jie Pan; Chunhua Liu; Zipeng Gong; Jing Huang; Jiang Zheng; Lin Zheng; Yongjun Li; Ting Liu; Yonglin Wang
Journal:  Molecules       Date:  2017-11-20       Impact factor: 4.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.